Immune checkpoint therapy enhances the anti-tumor effect in the tumor microenvironment by regulating the function of T cells (Sharma and Allison, 2015).In a preclinical drug experiment, it was found that the ICOS-ICOSLG pathway has a good clinical application prospect for immunotherapy of various tumors (Solinas et al., 2020). This evidence concerns the gene ICOSLG and neoplasm.